Background: The extent of variability in treatment suggestions for melanocytic lesions made by pathologists is unknown.
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Understanding why pathologists make treatment suggestions provides insight into patient care practices. Currently, little is known about how often pathologists make suggestions or whether these suggestions are consistent with national guidelines. Given wide variability in surgical and nonsurgical therapies for melanocytic lesions [1] [2] [3] and lack of consensus for both diagnosis and treatment of various types of atypical/ dysplastic nevi, [3] [4] [5] [6] understanding pathologists' suggestions could provide valuable insight. To further complicate matters, terminology for melanocytic lesions lacks standardization and is reflected in poor interobserver reproducibility for borderline tumors with unclear malignant potential. [7] [8] [9] [10] [11] Some pathologists have also proposed abandoning the grading system of dysplastic nevi entirely, given the ambiguity of the connotations associated with ''mild'' or ''moderate'' dysplastic nevi. 12 Lesions with the same diagnosis, such as Spitz nevi, can vary in pathologic characteristics and pathologists may make recommendations to better guide treatment for these lesions.
Understanding whether such motivations underlie treatment recommendations will help guide the patient's physician in making a decision on the course of treatment. In addition, although the National Comprehensive Cancer Network (NCCN) 13 has established recommendations for the treatment of melanoma in situ and melanoma, it remains unclear whether treatments currently suggested by pathologists are in accordance with these standards. [14] [15] [16] Recognizing variation in diagnostic thresholds, interpretation, and treatment suggestions for the wide spectrum of melanocytic skin lesions, Piepkorn et al 17 proposed the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme in 2014 to reduce complexity and improve pathology reporting of these neoplasms. This schema stratifies melanocytic lesions into 5 broad categories based on histologic findings and treatment suggestions. Example diagnoses (and suggested treatments) for the MPATH-Dx categories are as follows: dysplastic nevus with mild cytologic atypia in category 1 (no further treatment); dysplastic nevus with moderate cytologic atypia and conventional Spitz nevus in category 2 (narrow but complete re-excision suggested); dysplastic nevus with severe cytologic atypia, atypical Spitzoid lesion, and melanoma in situ in category 3 repeat (excision with at least 5-mm margins suggested); and invasive melanoma in categories 4 and 5 (wide excision with at least 1-cm margins). [17] [18] [19] [20] There is a knowledge gap in the reasons why and how often pathologists provide treatment suggestions. Understanding these underlying reasons and the consistency or variability in these suggestions can help a physician triage care for pigmented lesions, particularly for lesions without nationally recognized treatment guidelines. Furthermore, data on standard treatment suggestions can serve as a starting point for clinical trials aimed at understanding the appropriate treatment of pigmented lesions. The primary objective of this study is to determine how often and why practicing pathologists render treatment suggestions in their final pathology reports, what suggestions are provided, and how often the suggestions align with NCCN guidelines for melanoma.
METHODS
Data were obtained from responses to a crosssectional survey of practicing pathologists enrolled in the M-Path study, which was designed to assess the variability in pathology diagnoses. The M-Path study survey recruitment methods were previously described in detail. 21 Briefly, a survey was sent to eligible pathologists practicing in 10 US states (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Utah, and Washington) over a 1-year period (July 2013-August 2014). Inclusion in the study required interpreting melanocytic skin lesions in the past year and plans to continue over the next 2 years. Medical students, residents, and fellows in training were ineligible. This study was approved by the institutional review boards of The lack of consistency in treatment recommendations leads to the potential for undertreatment or overtreatment of melanocytic lesions.
Health and Sciences University, Rhode Island Hospital, and Dartmouth College.
The survey examined individual demographic and practice characteristics, including age and gender, training and type of work environment, and experience and confidence in interpreting melanocytic skin lesions. The survey also included questions on several topics relevant to the field of dermatology: whole slide digital imaging, medical malpractice, second opinions, factors influencing diagnoses, and treatment suggestions. To capture current behavior, physicians were asked how often they reported treatment suggestions regarding re-excision margins and reasons for inclusion/ exclusion of these suggestions. To understand how treatment suggestions are being used relative to specific diagnoses, physicians were asked, ''Assuming positive biopsy margins, what treatment would you recommend for the following diagnoses if the provider asked your opinion?'' Respondents could then indicate their suggestions for mildly, moderately, and severely atypical dysplastic nevi, conventional Spitz nevi, atypical Spitz lesions, melanoma in situ, and invasive melanoma. A complete copy of the survey is available online. 22 Responses regarding frequency of including treatment suggestions were grouped a priori into 4 categories: 0%, 1% to 5%, 6% to 49%, and 50% or more. The Kruskal-Wallis test was used to test for associations between this variable and physician characteristics. Spearman rank correlation was used to test for monotonic trends in the percent of total pathology reports that included treatment suggestions across physician characteristics. To investigate compliance with national guidelines for melanoma, we determined if the treatment selected by the physician was less than recommended standards (undertreatment), agreed with the national standards (congruent treatment), or represented surgical margins beyond those suggested by national standards (overtreatment). Treatment suggestions for melanoma in situ were treated as an ordinal variable (undertreatment, agree, overtreatment) and analyzed using the Kruskal-Wallis test to determine associations with physician characteristics. Associations between invasive melanoma treatment suggestions and physician characteristics were assessed using x 2 or Fisher exact test where appropriate. All analyses were conducted using software (SAS, Version 9.4, SAS Institute Inc, Cary, NC), and all statistical tests were 2-tailed with a = .05.
RESULTS
Of 301 eligible pathologists, 207 (69%) enrolled in the study. The mean age of participants was 51 years, with 123 men (59%) and 59 individuals (29%) affiliated with an academic medical center. Board certification or fellowship training in dermatopathology was reported by 81 (39%) ( Table I ). Of 207 survey respondents, 79 (38%) indicated that they were board certified in dermatopathology. Of these 79 respondents, 21 (27%) also indicated that they were board certified in dermatology. Of the 21 respondents, 4 (19%) noted that they also were board certified in anatomic and clinical pathology. Thus, 17 of the 207 survey respondents (8%) completed dermatology residencies whereas 4 of the 207 survey respondents (2%) completed both dermatology and pathology residencies.
Pathologists varied in their inclusion of treatment suggestions in final pathology reports. Approximately 15% (n = 32) reported never including treatment suggestions, whereas the remainder included treatment suggestions by varying degrees: 24% of pathologists (n = 50) reported including suggestions in 1% to 5% of reports, 35% (n = 73) reported including suggestions in 6% to 49% of reports, and 25% (n = 52) reported including suggestions in 50% or more of reports. Among the 52 pathologists who included suggestions in the majority of their reports, 14 (7%) reported always including them. Reasons given for providing suggestions included: improved patient care (n = 164, 79%), clarification of treatment options for the biopsying clinician (n = 140, 68%), and protection from legal liability (n = 81, 39%). Reasons for not providing suggestions in reports included: referring physicians did not want recommendations in the pathology report (n = 100, 48%), insufficient clinical information (n = 92, 44%), and lack of requisite clinical expertise (n = 60, 29%). Pathologists significantly more likely to include treatment suggestions were board certified or fellowship trained in dermatopathology and those with a higher melanocytic lesion caseload ($10%). For mild and moderate dysplastic nevi, pathologists with board certification or considered an expert by their colleagues trended toward offering more conservative treatment recommendations (both P \.05).
The distribution of suggested treatments by melanocytic lesion type is shown in Fig 1. Pathologists (Table II) . Pathologists with board certification or fellowship training in dermatopathology and a monthly caseload of 50% or more benign melanocytic skin lesions were more likely to suggest treatments consistent with the NCCN guidelines for melanoma in situ treatment (P \.001 and = .001, respectively). Those who undertreated melanoma in situ tended to have fewer years of experience interpreting melanocytic lesions, interpret less than 50 benign melanocytic lesions per month, and had a caseload of less than 10% melanocytic lesions per month (Table II) .
For invasive melanoma, 14 (7%) pathologists made treatment suggestions that would have undertreated lesions based on NCCN guidelines. Pathologist characteristics associated with treatment suggestions inconsistent with NCCN guidelines for invasive melanoma were age 50 years or older (P = .02) and more years of experience interpreting melanocytic skin lesions (P = .03) (Table II) .
DISCUSSION
Our results show variability in providing treatment suggestions among pathologists. In addition, this study highlights the wide range of treatment suggestions for melanocytic lesions that lack national treatment guidelines. 23, 24 Physician experience and training influenced whether pathologists made suggestions, with dermatopathology training trending toward more conservative treatment suggestions for mild and moderately dysplastic nevi. For melanomas and melanoma in situ, pathologists typically made treatment suggestions in accordance with the established NCCN guidelines. 25, 26 However, some pathologists made recommendations that would have undertreated or overtreated these melanocytic lesions.
A group of pathologists (15%) replied that they never made treatment suggestions, whereas another group of pathologists (7%) always did. Patient care motivations, including improving patient care and clarifying treatment suggestions, represented prominent reasons for making recommendations. 27 Preference of the referring physician was the main reason for not making treatment suggestions, with 48% of pathologists noting this as the primary reason. For pathologists who do not make treatment suggestions, other reasons included not having enough clinical information or expertise. Pathologists with more clinical experience (eg, dermatopathology training and higher monthly caseload of melanocytic lesions) were more likely to include treatment suggestions in their report. We also noted that older pathologists and those with (9) 157 (76) 32 (15) 14 (7) 193 (93) Age, y \50 7 (7) 72 (76) 16 (17) 2 (2)* 93 (98)* $50
11 (10) 85 (76) 16 (14) 12 (11) The lack of diagnostic and treatment consensus for some types of dysplastic nevi and Spitz lesions is reflected in this survey. [1] [2] [3] 17, [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] Pathologists may prefer to call borderline lesions ''atypical'' instead of ''malignant,'' while also erring on the side of caution and recommending re-excision with appropriate margins. This strategy ensures that the tumor is treated with surgical excision while also preventing the patient from carrying a malignant cancer diagnosis in their medical record.
Of most concern is the lack of consistency in treatment suggestions for melanoma in situ and invasive melanoma, with 24% of pathologists' recommendations differing from NCCN criteria for melanoma in situ. Although the majority (90%) of board-certified or fellowship-trained pathologists suggested treatment in agreement with guidelines for melanoma in situ, only 67% of physicians with board certification or training in a different specialty matched the treatment recommendations. Another potential explanation for inconsistencies in recommendations and national guidelines may be changes in the treatment of melanoma over time, as evidenced by the Surveillance, Epidemiology, and End Results data. 46-48 From 1973 46-48 From to 1985 , the majority of melanoma in situ cases were treated with excisional biopsy. In contrast, from 1996 to 2006, the majority of melanoma in situ cases were treated with less than 1-cm excisional margins, which is consistent with NCCN treatment guidelines. 48 In our study, 9% of pathologists recommended undertreatment of melanoma in situ.
This study has several limitations. We assessed self-reported perceptions, not actual clinical practice; thus, some response bias could affect these findings. In addition, our findings cannot be generalized to other pathology subspecialties. The survey asked for treatment suggestions, assuming the provider asked the pathologist for a recommendation. Another limitation is the considerable variability within lesions of the same category such as atypical Spitz tumors. 8 Pathologists examine slides and use the degree of atypia in formulating their treatment suggestions. Our survey did not provide photographs or slides of actual lesions to help pathologists guide treatment suggestions. Treatment recommendations are also frequently more consistent than diagnostic terminology. Our study provided a uniform diagnostic terminology, and a list of treatment recommendation options. Treatment recommendations may be more consistent when pathologists are examining actual slides as compared with our study. 18, 19 Further, the treatment options on the M-Path study survey are not always reflective of everyday practice for pathologists. 19 Pathologists were limited to choosing from limited options for treatment recommendations. Thus, a pathologist who normally recommends ''re-excision with appropriate margins'' without giving specific margins may have checked ''no recommendation'' based on the treatment options presented by the survey.
Strengths of our study included a survey response rate of 69% of eligible invitees, which is higher than national standards for physician surveys. 49 Our data were also gathered from 10 geographically diverse US states and included responses from both academic and community pathologists.
Our study results may largely reflect uncertainty in the evidence-based literature regarding treatment of these lesions. Our findings point to a potential gap in use of guideline treatment recommendations and the persistent challenge that clinicians face with the intermediate melanocytic lesions.
